Chi K - Search Results

1

Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.

Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Waterhouse DN, et al. Among authors: chi k. Curr Cancer Drug Targets. 2006 Sep;6(6):455-89. doi: 10.2174/156800906778194586. Curr Cancer Drug Targets. 2006. PMID: 17017873 Review.

2

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.

Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. Chi KN, et al. Invest New Drugs. 2005 Aug;23(4):311-5. doi: 10.1007/s10637-005-1439-x. Invest New Drugs. 2005. PMID: 16012790 Clinical Trial.

3

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC. Batist G, et al. Among authors: chi kn. Clin Cancer Res. 2009 Jan 15;15(2):692-700. doi: 10.1158/1078-0432.CCR-08-0515. Clin Cancer Res. 2009. PMID: 19147776 Clinical Trial.

4

Novel targeted therapies for prostate cancer.

Macfarlane RJ, Chi KN. Macfarlane RJ, et al. Urol Clin North Am. 2010 Feb;37(1):105-19, Table of Contents. doi: 10.1016/j.ucl.2009.11.011. Urol Clin North Am. 2010. PMID: 20152524 Review.

5

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L. Bernstein V, et al. Among authors: chi k. Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13. Breast Cancer Res Treat. 2018. PMID: 29027598 Clinical Trial.

6

Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.

Al-Karim HA, Tan KE, Chi KN, Bryce CJ, Murray NR, Coppin C. Al-Karim HA, et al. Am J Clin Oncol. 2002 Oct;25(5):515-9. doi: 10.1097/00000421-200210000-00019. Am J Clin Oncol. 2002. PMID: 12393996

7

Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.

Chi KN. Chi KN. World J Urol. 2005 Feb;23(1):33-7. doi: 10.1007/s00345-004-0477-x. Epub 2005 Feb 19. World J Urol. 2005. PMID: 15723221 Review.

8

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

9

Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.

Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. Al-Tourah AJ, et al. J Urol. 2005 Dec;174(6):2209-13, discussion 2213. doi: 10.1097/01.ju.0000181810.22617.f8. J Urol. 2005. PMID: 16280765

10

Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.

Gleave M, Chi KN. Gleave M, et al. Ann N Y Acad Sci. 2005 Nov;1058:1-15. doi: 10.1196/annals.1359.001. Ann N Y Acad Sci. 2005. PMID: 16394121 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

886 results

Search Page